Clinical Trials Directory

Trials / Unknown

UnknownNCT04705298

Role of the Gut Microbiota in Pediatric Epilepsy

Leveraging the Gut Microbiota in Pediatric Refractory Epilepsy: Safety and Feasibility of Oligofructose-enriched Inulin Supplementation for Dysbiosis and Seizure Control

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
British Columbia Children's Hospital · Academic / Other
Sex
All
Age
2 Years – 18 Years
Healthy volunteers
Accepted

Summary

Nearly a third of children with epilepsy are refractory to pharmacotherapy. The ketogenic diet (KD) is a highly effective alternative therapy reducing seizure frequency by 50% in more than half of treated children. The exact mechanisms of KD remain poorly understood, and recent studies have implicated the gut microbiota (GM). This pilot study aims to determine the feasibility of a 12-week dietary intervention with prebiotic fiber in children with epilepsy. The investigators hypothesize that consumption of inulin will alter gut microbiota and may have effects on seizure frequency.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPrebioticOligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
DIETARY_SUPPLEMENTPlaceboMaltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years

Timeline

Start date
2021-06-01
Primary completion
2022-09-01
Completion
2022-09-01
First posted
2021-01-12
Last updated
2022-03-09

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04705298. Inclusion in this directory is not an endorsement.